TFPI
ENSG00000003436
Target class
Unclassified protein
Chromosome
2
Approved drugs
3
Clinical candidates (approved and in development)
4
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- No
- Target name
- TFPI
- Gene name
- Tissue factor pathway inhibitor
- Gene symbol
- TFPI
- Previous gene symbols
- LACI
- Protein name
- Tissue factor pathway inhibitor (TFPI) (Extrinsic pathway inhibitor) (EPI) (Lipoprotein-associated coagulation inhibitor) (LACI)
- EPI
- TFI
- TFPI1
- Gene biotype
- Protein coding
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 43
- Highest tissue expression
- 126.79
- Tissue specificity (Gini)
- 0.542
- Tissue specificity (tau)
- 0.843
- KEGG gene identifiers
- hsa:7035
- Protein interaction confidence
- 0.816542
- Protein interaction partners
- 24
- End position
- 187565846
- Start position
- 187463823
- Chromosome
- 2
- Strand
- Reverse
- [Isoform Alpha]: Secreted.
- SUBCELLULAR LOCATION: [Isoform Beta]: Microsome membrane
- Lipid-anchor, GPI-anchor .
Publication evidence
- PubMed 22144186
- Tissue specificity (tau)
- 0.84344
- Expression inequality (Gini)
- 0.54167
Expression in transcripts per million
- Lung
- 126.79
- Cells - Cultured fibroblasts
- 77.24
- Liver
- 58.72
- Artery - Coronary
- 54.13
- Adipose - Subcutaneous
- 52.98
Expression in transcripts per million
- Lung126.79
- Cells - Cultured fibroblasts77.24
- Liver58.72
- Artery - Coronary54.13
- Adipose - Subcutaneous52.98
- Adipose - Visceral (Omentum)45.04
- Breast - Mammary Tissue44.68
- Fallopian Tube43.23
- Thyroid42.01
- Nerve - Tibial41.94
- Cervix - Ectocervix41.62
- Cervix - Endocervix39.39
- Artery - Tibial37.84
- Bladder33.33
- Esophagus - Gastroesophageal Junction32.16
- Vagina30.92
- Small Intestine - Terminal Ileum29.7
- Uterus29.69
- Artery - Aorta29.19
- Esophagus - Muscularis26.59
- Kidney - Medulla23.12
- Ovary21.06
- Colon - Sigmoid19.35
- Spleen17.61
- Kidney - Cortex17.54
And 29 more, listed on the interactive page.
- GO:0007596
- GO:0030195
- GO:0071383
- GO:0005576
- GO:0005886
- GO:0005901
- GO:0009986
Molecular functions
- GO:0004866
Related records
Trials (44)
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
- A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
- A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
- A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
- A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure
- A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device
- A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
- A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
- A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
- A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
- A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
- Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
- Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed
- Compassionate Use of Concizumab if You Have Haemophilia
- Dose Escalation Study of PF-06741086 In Healthy Subjects
- Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects
Drugs (4)
- Andexanet alfa Tissue factor pathway inhibitor inhibitor
- BAY-1093884 Tissue factor pathway inhibitor inhibitor
- Concizumab Tissue factor pathway inhibitor inhibitor
- Marstacimab Tissue factor pathway inhibitor inhibitor